Introduction: Limited data exist regarding the use of the CardioCel 3D 60 patch in aortic arch reconstruction for congenital heart defects. Objectives: To assess the safety , efficacy , and clinical outcomes associated with the CardioCel 3D 60 patch in aortic arch repair. Methods: A single-center retrospective study included 60 consecutive patients undergoing aortic arch reconstruction with the CardioCel 3D 60 patch at the Children’s University Hospital in Krakow (October 2018–October 2024). The most prevalent diagnoses were hypoplastic left heart syndrome (n=24, 40.7%), hypoplastic aortic arch (n=17 , 28.8%), atrioventricular canal defects (n=6, 10.2%), interrupted aortic arch (n=5, 8.5%), and other anomalies (n=8, 13.3%). Results: Thirty-day mortality was 3.3% (n=2). Re-coarctation occurred in 28.3% (n=17) at a median of 147 days [83–181], requiring catheter-based reintervention in 20% (n=12), surgical reoperation in 1.7% (n=1), and combined approaches in 5% (n=3). The cohort comprised 53.3% males (n=32), with a median age of 12 days [IQR 8–57] and median weight of 3600 g [3000–4380] at surgery . Preoperative echocardiography showed median ascending aorta, transverse arch, and isthmus diameters of 4.7 mm [3–6.7], 4.0 mm [3.4–4.5], and 2.1 mm [1.8–3.4], respectively . Median cardiopulmonary bypass time was 114 minutes [88–147], with selective cerebral perfusion used in 29.6% (n=16). Median ICU and hospital stays were 15 [8–36] and 39.5 [26–74] days, respectively . Conclusions: The CardioCel 3D 60 patch demonstrates feasibility in aortic arch reconstruction in infancy but is associated with non-negotiable re-coarctation rates, underscoring the need for vigilant surveillance and tailored reintervention strategies.